However, MEK inhibition alone is reported to be sufficient to suppress the metastatic spread of Pten-deleted and KRas activated stem/progenitor murine prostate cancer cells orthotopically transplanted in vivo, similarly to combined mTORC1 and MEK inhibition [101]. This evidence concerns the gene MAP2K7 and prostate carcinoma.